Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial

Fig. 1

Study design. aRandomization stratified by geographic regions (North America and Western Europe; Japan; Republic of Korea and Taiwan; Latin America; rest of world). bIn a blinded manner. ADL-EU, reference adalimumab sourced from the European Union; ADL-PF, PF-06410293; EOT, end of treatment

Back to article page